Polymorphisms of sepiapterin reductase gene alter promoter activity and may influence risk of bipolar disorder

Patrick C McHugh, Peter R Joyce, Martin R Kennedy

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

OBJECTIVES: In a previous investigation, we observed altered expression of sepiapterin reductase (SPR) in cultured neural cells chronically exposed to paroxetine. SPR is an enzyme, which catalyzes the final step in the synthesis of tetrahydrobiopterin (BH4). BH4 is an essential cofactor for synthesis of many neurotransmitters including serotonin. Given the pivotal role of SPR in neurotransmitter production, we sought to test the hypothesis that SPR would influence susceptibility to mood disorders and patient response to antidepressants.

METHODS: We tested for association of SPR promoter polymorphisms with antidepressant response in a well-characterized triad cohort of mood disorders. We evaluated the functional effect of these variants using the Dual-Luciferase Reporter Gene Assay System in two independent cell lines.

RESULTS: Two promoter single nucleotide polymorphisms (rs1876487 and rs2421095) in SPR were identified that occurred in three distinct haplotypes. We found a statistically significant association of haplotype pair 2,3 with bipolar I disorder [odds ratio: 5.47; 95% confidence interval: (1.68-17.88); P<0.005] and the personality measure self-transcendence (P = 0.020). Moreover, we found preliminary evidence that individuals with haplotype pair 2,3 responded better to the treatment with selective serotonin reuptake inhibitors. Reporter gene assays revealed a 1.4-fold to 1.6-fold decrease in the transcription rate of the two less common haplotypes (2 and 3) compared with haplotype 1, in the two cell lines investigated.

CONCLUSION: This reduced transcription rate for SPR promoter haplotypes 2 and 3 may impact on BH4-mediated neurotransmitter production, thus suggesting a biological process through which SPR gene variants might influence antidepressant response and susceptibility to bipolar disorder.

Original languageEnglish
Pages (from-to)330-7
Number of pages8
JournalPharmacogenetics and Genomics
Volume19
Issue number5
Publication statusPublished - May 2009
Externally publishedYes

Fingerprint

sepiapterin reductase
Bipolar Disorder
Haplotypes
Genes
Antidepressive Agents
Neurotransmitter Agents
Mood Disorders
Reporter Genes
Biological Phenomena
Cell Line
Paroxetine
Serotonin Uptake Inhibitors
Luciferases
Single Nucleotide Polymorphism
Personality
Cultured Cells

Cite this

@article{3643cf53ebc74ea9a2f8c0a8c8aa1299,
title = "Polymorphisms of sepiapterin reductase gene alter promoter activity and may influence risk of bipolar disorder",
abstract = "OBJECTIVES: In a previous investigation, we observed altered expression of sepiapterin reductase (SPR) in cultured neural cells chronically exposed to paroxetine. SPR is an enzyme, which catalyzes the final step in the synthesis of tetrahydrobiopterin (BH4). BH4 is an essential cofactor for synthesis of many neurotransmitters including serotonin. Given the pivotal role of SPR in neurotransmitter production, we sought to test the hypothesis that SPR would influence susceptibility to mood disorders and patient response to antidepressants.METHODS: We tested for association of SPR promoter polymorphisms with antidepressant response in a well-characterized triad cohort of mood disorders. We evaluated the functional effect of these variants using the Dual-Luciferase Reporter Gene Assay System in two independent cell lines.RESULTS: Two promoter single nucleotide polymorphisms (rs1876487 and rs2421095) in SPR were identified that occurred in three distinct haplotypes. We found a statistically significant association of haplotype pair 2,3 with bipolar I disorder [odds ratio: 5.47; 95{\%} confidence interval: (1.68-17.88); P<0.005] and the personality measure self-transcendence (P = 0.020). Moreover, we found preliminary evidence that individuals with haplotype pair 2,3 responded better to the treatment with selective serotonin reuptake inhibitors. Reporter gene assays revealed a 1.4-fold to 1.6-fold decrease in the transcription rate of the two less common haplotypes (2 and 3) compared with haplotype 1, in the two cell lines investigated.CONCLUSION: This reduced transcription rate for SPR promoter haplotypes 2 and 3 may impact on BH4-mediated neurotransmitter production, thus suggesting a biological process through which SPR gene variants might influence antidepressant response and susceptibility to bipolar disorder.",
keywords = "Adult, Aged, Alcohol Oxidoreductases/genetics, Animals, Bipolar Disorder/genetics, COS Cells, Cercopithecus aethiops, Cohort Studies, Family, Female, Genetic Predisposition to Disease, Humans, Male, Middle Aged, Models, Biological, Polymorphism, Single Nucleotide/physiology, Promoter Regions, Genetic/genetics, Risk Factors",
author = "McHugh, {Patrick C} and Joyce, {Peter R} and Kennedy, {Martin R}",
year = "2009",
month = "5",
language = "English",
volume = "19",
pages = "330--7",
journal = "Pharmacogenetics and Genomics",
issn = "1744-6872",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

Polymorphisms of sepiapterin reductase gene alter promoter activity and may influence risk of bipolar disorder. / McHugh, Patrick C; Joyce, Peter R; Kennedy, Martin R.

In: Pharmacogenetics and Genomics, Vol. 19, No. 5, 05.2009, p. 330-7.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Polymorphisms of sepiapterin reductase gene alter promoter activity and may influence risk of bipolar disorder

AU - McHugh, Patrick C

AU - Joyce, Peter R

AU - Kennedy, Martin R

PY - 2009/5

Y1 - 2009/5

N2 - OBJECTIVES: In a previous investigation, we observed altered expression of sepiapterin reductase (SPR) in cultured neural cells chronically exposed to paroxetine. SPR is an enzyme, which catalyzes the final step in the synthesis of tetrahydrobiopterin (BH4). BH4 is an essential cofactor for synthesis of many neurotransmitters including serotonin. Given the pivotal role of SPR in neurotransmitter production, we sought to test the hypothesis that SPR would influence susceptibility to mood disorders and patient response to antidepressants.METHODS: We tested for association of SPR promoter polymorphisms with antidepressant response in a well-characterized triad cohort of mood disorders. We evaluated the functional effect of these variants using the Dual-Luciferase Reporter Gene Assay System in two independent cell lines.RESULTS: Two promoter single nucleotide polymorphisms (rs1876487 and rs2421095) in SPR were identified that occurred in three distinct haplotypes. We found a statistically significant association of haplotype pair 2,3 with bipolar I disorder [odds ratio: 5.47; 95% confidence interval: (1.68-17.88); P<0.005] and the personality measure self-transcendence (P = 0.020). Moreover, we found preliminary evidence that individuals with haplotype pair 2,3 responded better to the treatment with selective serotonin reuptake inhibitors. Reporter gene assays revealed a 1.4-fold to 1.6-fold decrease in the transcription rate of the two less common haplotypes (2 and 3) compared with haplotype 1, in the two cell lines investigated.CONCLUSION: This reduced transcription rate for SPR promoter haplotypes 2 and 3 may impact on BH4-mediated neurotransmitter production, thus suggesting a biological process through which SPR gene variants might influence antidepressant response and susceptibility to bipolar disorder.

AB - OBJECTIVES: In a previous investigation, we observed altered expression of sepiapterin reductase (SPR) in cultured neural cells chronically exposed to paroxetine. SPR is an enzyme, which catalyzes the final step in the synthesis of tetrahydrobiopterin (BH4). BH4 is an essential cofactor for synthesis of many neurotransmitters including serotonin. Given the pivotal role of SPR in neurotransmitter production, we sought to test the hypothesis that SPR would influence susceptibility to mood disorders and patient response to antidepressants.METHODS: We tested for association of SPR promoter polymorphisms with antidepressant response in a well-characterized triad cohort of mood disorders. We evaluated the functional effect of these variants using the Dual-Luciferase Reporter Gene Assay System in two independent cell lines.RESULTS: Two promoter single nucleotide polymorphisms (rs1876487 and rs2421095) in SPR were identified that occurred in three distinct haplotypes. We found a statistically significant association of haplotype pair 2,3 with bipolar I disorder [odds ratio: 5.47; 95% confidence interval: (1.68-17.88); P<0.005] and the personality measure self-transcendence (P = 0.020). Moreover, we found preliminary evidence that individuals with haplotype pair 2,3 responded better to the treatment with selective serotonin reuptake inhibitors. Reporter gene assays revealed a 1.4-fold to 1.6-fold decrease in the transcription rate of the two less common haplotypes (2 and 3) compared with haplotype 1, in the two cell lines investigated.CONCLUSION: This reduced transcription rate for SPR promoter haplotypes 2 and 3 may impact on BH4-mediated neurotransmitter production, thus suggesting a biological process through which SPR gene variants might influence antidepressant response and susceptibility to bipolar disorder.

KW - Adult

KW - Aged

KW - Alcohol Oxidoreductases/genetics

KW - Animals

KW - Bipolar Disorder/genetics

KW - COS Cells

KW - Cercopithecus aethiops

KW - Cohort Studies

KW - Family

KW - Female

KW - Genetic Predisposition to Disease

KW - Humans

KW - Male

KW - Middle Aged

KW - Models, Biological

KW - Polymorphism, Single Nucleotide/physiology

KW - Promoter Regions, Genetic/genetics

KW - Risk Factors

M3 - Article

VL - 19

SP - 330

EP - 337

JO - Pharmacogenetics and Genomics

JF - Pharmacogenetics and Genomics

SN - 1744-6872

IS - 5

ER -